Core Viewpoint - Haier Biomedical is leading the green transformation in the life sciences industry by launching innovative technologies and establishing a collaborative ecosystem for sustainable development [1][5]. Group 1: Technological Innovation - Haier Biomedical has established a foundation of green and technological advancement since 2005, breaking a 30-year foreign monopoly with the development of China's first ultra-low temperature storage box [2]. - The newly launched Eco-Drive ultra-green technology improves energy efficiency by 30% compared to the highest current industry standards, achieving the top rank in global energy efficiency [2]. - The AI-driven temperature and humidity control system for drug stability has increased energy efficiency by 80%, saving nearly 40,000 yuan in electricity costs annually for ten devices [3]. Group 2: Industry Standards and Certifications - Haier Biomedical has received multiple certifications, including 44 Energy Star certifications and 116 energy-saving environmental protection certificates, showcasing its commitment to sustainability [4]. - The company has been recognized in the S&P Global "Sustainability Yearbook (China Edition)" for three consecutive years, highlighting its leadership in green practices within the biomedicine sector [4]. Group 3: Collaborative Ecosystem - The company has initiated a green ecological co-construction initiative in collaboration with authoritative organizations like Ernst & Young and UL, aiming to promote green standards and practices across the industry [5][6]. - Haier Biomedical's solar vaccine refrigerator solution serves over 45 million children annually in more than 80 countries along the Belt and Road, addressing vaccine storage challenges in regions with inadequate power supply [7]. Group 4: Global Market Performance - In the first three quarters of this year, Haier Biomedical's overseas market revenue reached 634 million yuan, reflecting a year-on-year growth of 20.18%, driven by its green technology [7].

Core Viewpoint - The low-temperature storage industry is under pressure, with Haier Biomedical reporting a decline in revenue and net profit for the first half of 2025, but showing signs of recovery compared to the second half of the previous year [1][2]. Financial Performance - Haier Biomedical's revenue for the first half of 2025 was 1.196 billion yuan, a year-on-year decrease of 2.27%, while net profit attributable to shareholders was 143 million yuan, down 39.09% [1]. - Despite the decline, revenue from low-temperature storage increased by 16.73% compared to the second half of the previous year [1]. New Industry Development - The proportion of revenue from new industries rose from 38% in 2023 to 47% in the first half of 2025, an increase of 7.27 percentage points year-on-year [2]. - Haier Biomedical has been actively acquiring companies in various sectors, including blood collection, temperature control, and laboratory solutions, to expand its new industry segment [3]. Market Position and Share - Haier Biomedical holds over 50% market share in plasma collection solutions and ranks among the top three in the automated medication market [4]. - The company has seen significant growth in its laboratory solutions, with its total organic carbon analyzers and UV spectrophotometers leading the domestic market [4]. International Expansion - Haier Biomedical is pursuing international markets with a localized strategy, having established a presence in over 150 countries and regions [5]. - In the first half of 2025, overseas revenue reached 427 million yuan, a year-on-year increase of 30.17%, with the second quarter showing a remarkable growth of 56.67% [6]. Future Outlook - The company anticipates further growth in overseas markets, particularly in Southeast Asia and the Middle East, driven by the expansion of medical infrastructure and the promotion of new industry solutions [7].